Enoxaparin utilization evaluation: An observational prospective study in medical inpatients

Iranian Journal of Pharmaceutical Research

Volumn 7, Issue 1, 2008, Pages 77-82

  Fahimi, Fanak ^a   Baniasadi, Shadi ^a   Behzadnia, Neda ^a   Varahram, Fatemeh ^a   Ghazi Tabatabaie, Leila ^a  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Appropriate drug use; Drug utilization evaluation; Enoxaparin; Prescription pattern

Indexed keywords

ANTITHROMBOCYTIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENOXAPARIN; HEPARIN; WARFARIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG DOSE REGIMEN; DRUG SUBSTITUTION; DRUG USE; DRUG WITHDRAWAL; EDUCATION PROGRAM; FEMALE; HEMOPTYSIS; HOSPITAL PATIENT; HUMAN; IRAN; KIDNEY FAILURE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MELENA; OBSERVATIONAL STUDY; PRESCRIPTION; PROSPECTIVE STUDY; TEACHING HOSPITAL; VENOUS THROMBOEMBOLISM;

EID: 69749098070     PISSN: 17350328     EISSN: 17266890     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Soumerai SB and Avorn J. Efficacy and cost-containment in hospital pharmacotherapy: state of the art and future directions. Milbank Mem. Fund. Q. Health. Soc. (1984) 62: 447-74
2. Soumerai SB, McLaughlin TJ and Avorn J. Improving drug prescribing in primary care: a critical analysis of the experimental literature. Milbank. (1989) 67: 268-317
3. Hennessy-S, Strom BL, Lipton HL and Lipton HL. Drug utilization review. In: Strom BL. (ed.) Pharmacoepidemiology. 3rd ed. Johh Wiley & Sons Ltd, New York (2000) 505-23
4. Rational Pharmaceutical Management Plus Program. Identifying Problems with Drug Use. In: Drugs and Therapeutics Committee Training Course [serial online] Management Sciences for Health, Arlington, VA. Available from: URL: http://www1.msh.org/projects/rpmplus/Documents/ upload/DTC-Training-Course-Session-7.pdf. [cited 2007 May 26]
5. Jetha L. A drug usage review of therapeutic doses of enoxaparin at Barnet and Chase Farm Hospitals. London pharmacy education and training pzifer project awards [online] 2007[cited 2007 Nov 8]. Available from: http://www.londonpharmacy.nhs.uk/educationandtraining/prereg/ pfizerProjectAwards2007/leila%20jetha%20Barnet%20and%20Chase%20 Farm%20Hospital%20Trust.pdf
6. Dedden P, Chang B and Nagel D. Pharmacy-managed program for home treatment of deep vein thrombosis. Am. J. Health-System Pharm. (1997) 54: 1968-72
7. Deitcher SR, Kessler CM, Merli G, Rigas JR, Lyons RM and Fareed J. Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-Day Period. Clin. Appl. Thromb. Hemost. (2006) 12: 389-96
8. Pugh MJV, Fincke BG, Bierman AB, Chang BH, Rosen A, Cunningham F, Amuan M, Burk M and Berlowitz DR. Potentially inappropriate prescribing in elderly veterans: are we using the wrong drug, wrong dose, or wrong duration? J. Am. Geriatr. Soc. (2005) 53: 1282-1289
9. Rhône-Poulenc Rorer Canada Inc. Lovenox® (Enoxaparin) Product Monograph. Rhône-Poulenc Rorer Canada, Montreal (1999)
10. Antman EM, McCabe CH, Gurfinkel EP, Turpie AG, Bernink PJ, Salein D, Bayes De Luna A, Fox K, Lablanche JM, Radley D, Premmercur J and Braunwald E. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction: results of the thrombolysis in myocardial infarction (TIMI) i1B trial. Circulation (1999) 100: 1593-601
11. Witter MD, Gupchup GV, Dole JE, Singhal P, Singhal P and Black A. Pharmacoeconomic assessment of enoxaparin in the skilled ward of a long-term care facility versus unfractionated heparin in the hospital for treatment of proximal deep vein thrombosis. Consult. Pharm. [Serial online] 2000 Feb [cited 2007 May 15] 15:151-9 Available from: URL: http://www.ascp.com/publications/tcp/2000/feb/rr_pharm.shtml.
12. Haines ST, Racine E and Zeolla M. Venous thromboembolism. In: Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG and Posey L-M. (eds.) Pharmacotherapy: A Pathophysiologic Approach. 5nd ed. Mc Graw-Hill, New York (2002)
13. Gilbert KB and Rodgers GM. Utilization and outcomes of enoxaparin treatment for deep vein thrombosis in a tertiary cars hospital. Am. J. Hematil. (2000) 63: 285-288
14. Canadian Pharmacist Association. Enoxaparine monograph. In: Compendium of Pharmaceuticals and Specialties [database online] Toronto (2007). [Cited, 2007 May 10]. Available: from: URL: https://www.etherapeutics.ca/wps/portal/!ut/p/.scr/Login
15. Hirsh J and Raschke R. Heparin and low-molecular-weight heparin. Chest (2004) 126: 188S-203S
16. Buller HR, Agneili G, Hull RD, Hyers TM, Prins MH and Raskob GE. Antithrombotic therapy for venous thromboembolic disease. Chest (2004) 126: 401s-428s
17. Bowman L. Drug use evaluation is DUE: Healthcare utilization evaluation is over-DUE. Hosp. Pharm. [Serial online] 1996[cited 2007 May 12] 31: 347-53 Available from: URL: http://depts.washington.edu/expharmd/ ExPharmD_DUE.html
18. Sanderink GJ, Le Liboux A and Jariwala N. The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers. Clin. Pharmacol. Ther. (2002) 72: 308-18
19. Khazan M, Scheuering S, Adamson R and Mathis AS. Prescribing patterns and outcomes of enoxaparin for anticoagulation of atrial fibrillation. Pharmacotherapy (2003) 23: 651-58
20. Macie C, Forbes L, Foster GA and Douketis JD. Dosing practices and risk factors for bleeding in patients receiving enoxaparin for the treatment of an acute coronary syndrome. Chest (2004) 125: 1616-21
21. Koren-Michowitz M, Avni B, Michowitz Y, Moravski G, Efrati S and Golik A. Early onset of hyperkalemia in patients treated with low molecular weight heparin: a prospective study. Pharmacoepidemiol. Drug Saf. (2003) 13: 299-302
22. McKinney D and Garstang S. Prevention of thromboembolism in spinal cord injury. eMedicine [online] 2006 March 22 [cited 2007 June 8]. Available from: URL:http://www.emedicine.com/pmr/topic229.htm.